AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
← catalyst calendarNCT07668401 · readout in 876 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
400estimated
Sites
41
Countries
India, Japan, Malaysia +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2027-01-07 | estimated | When the study began enrolling |
| Primary completion | 2029-01-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-11 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Zenagamtide
- Drug: Placebo ( matched to Zenagamtide)
Primary outcome
what the primary-completion date above is the date OFRelative change in body weight
measured From baseline (week 0) to week 80
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed